DRL gears up for biosimilar push, consumer health growth post record FY25
Dr Reddy’s stock rose 5.5% in six sessions post-Q4 results, outperforming the BSE Healthcare index. Strong revenue growth, biosimilar launches, and semaglutide portfolio support long-term prospects despite Revlimid taper and reduced target prices by (...)
Site référencé: The Economic Times
The Economic Times
Equities seen outperforming in FY26 with 12–15% returns : Check key triggers, risks & strategy
20/05/2025
2 top stock recommendations from Rajesh Palviya
20/05/2025
Rich Dad, Poor Dad author warns U.S. debt downgrade signals 1929 Depression, urges buying gold, silver, Bitcoin
20/05/2025
Bilawal Bhutto being used as a pawn against India ? New, unexpected claims stir post-Pahalgam pot even as war fog settles
20/05/2025
Are fertilizer and QSR stocks poised for a comeback ? Neeraj Dewan answers
20/05/2025
Gold Price Prediction : Gold prices off Rs 6,500 from peak. Time to buy now ?
20/05/2025
